The Technical Analyst
Arctos NorthStar [ANAC]
Exchange: NYSE Sector: Financial Services Industry: Shell Companies
Arctos NorthStar Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.05% $10.19
America/New_York / 24 feb 2023 @ 15:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 419.43 mill |
| EPS: | 0.310 |
| P/E: | 32.87 |
| Earnings Date: | N/A |
| SharesOutstanding: | 41.16 mill |
| Avg Daily Volume: | 0.122 mill |
| RATING 2023-02-24 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 3.32x |
| Company: PE 32.87 | sector: PE 9.91 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 32.87 | industry: PE -11.98 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.18 - 10.20 ( +/- 0.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-03 | Collins Tomago | Sell | 25 000 | Class B ordinary shares |
| 2023-03-03 | Oconnor David Justin | Sell | 7 806 249 | Class B ordinary shares |
| 2023-03-03 | Smith Jared T | Sell | 25 000 | Class B ordinary shares |
| 2023-03-03 | Charles Ian Hunter | Sell | 7 806 249 | Class B ordinary shares |
| 2023-03-03 | Mcpherron Meredith Lazo | Sell | 25 000 | Class B ordinary shares |
| INSIDER POWER |
|---|
| -100.00 |
| Last 94 transactions |
| Buy: 532 726 | Sell: 34 267 049 |
Forecast:
01:40 - $10.21
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.19 (0.05% ) |
| Volume | 0.0007 mill |
| Avg. Vol. | 0.122 mill |
| % of Avg. Vol | 0.576 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ANAC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ANAC
Arctos NorthStar Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It focuses on sports, media, and entertainment sectors. The company was founded in 2020 and is based in Dallas, Texas.
Latest Press Releases
2016-05-04 16:01:00 - Press Release
Anacor Pharmaceuticals To Report First Quarter 2016 Financial Results
On May 10, 2016
Palo alto, calif.--(business wire)--anacor pharmaceuticals, inc. (nasdaq:anac) will release its financial results for the quarter ended march 31, 2016, before the market opens on tuesday, may 10, 2016. the announcement will be followed by a conference call at 8:00 a.m. et / 5:00 a.m. pt during which management will discuss anacor’s financial results and recent developments. the call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. the call will also be webcast live and may be accessed on the events and presentations page, under investors, on anacor’s website at www.anacor.com where it will be available for three months following the call...
2016-02-22 16:30:00 - Press Release
Anacor Pharmaceuticals Announces 2015 Fourth Quarter And Year-end
Financial Results Conference Call And Webcast
Palo alto, calif.--(business wire)--anacor pharmaceuticals, inc. (nasdaq:anac) will release its financial results for the fourth quarter and year ended december 31, 2015, after the market closes on monday, february 29, 2016. the announcement will be followed by a conference call at 5:00 p.m. et / 2:00 p.m. pt during which management will discuss anacor’s financial results and recent developments. the call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. the call will also be webcast live and may be accessed on the events and presentations page, under investors, on anacor’s website at www.anacor.com where it will be available for three months following the call...
2015-10-28 08:30:00 - Press Release
Anacor Pharmaceuticals To Report Third Quarter 2015 Financial Results
On November 3, 2015
Palo alto, calif.--(business wire)--anacor pharmaceuticals, inc. (nasdaq:anac) will release its financial results for the quarter ended september 30, 2015, before the market opens on tuesday, november 3, 2015. the announcement will be followed by a conference call at 8:00 a.m. et / 5:00 a.m. pt during which management will discuss anacor’s financial results and recent developments. the call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. the call will also be webcast live and may be accessed on the events and presentations page, under investors, on anacor’s website at www.anacor.com where it will be available for three months following the call...
2015-07-23 17:00:00 - Press Release
Anacor Pharmaceuticals To Report Second Quarter 2015 Financial
Results On August 6, 2015
Palo alto, calif.--(business wire)--anacor pharmaceuticals, inc. (nasdaq:anac) will release its financial results for the quarter ended june 30, 2015, after the close of market on thursday, august 6, 2015. the announcement will be followed by a conference call at 5:00 p.m. et / 2:00 p.m. pt during which management will discuss anacor’s financial results and recent developments. the call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. the call will also be webcast live and may be accessed on the events and presentations page, under investors, on anacor’s website at www.anacor.com where it will be available for three months following the call...
2015-07-13 07:00:00 - Press Release
Anacor Pharmaceuticals Announces Positive Top-line Results From Two
Phase 3 Pivotal Studies Of Crisaborole Topical Ointment, 2% In Patients
With Mild-to-moderate Atopic Dermatitis
Palo alto, calif.--(business wire)--anacor pharmaceuticals, inc. (nasdaq:anac) today announced preliminary top-line results from its two phase 3 pivotal studies of crisaborole topical ointment, 2% (formerly an2728), a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (pde-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. in both studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and demonstrated a safety profile consistent with previous studies. summary of primary and secondary phase 3 pivotal study results study ad-301 (crisaborole /vehicle)n=503 / 256 (crisaborole /vehicle)n=513 / 250 32...